206 related articles for article (PubMed ID: 11742063)
21. Charged bipolar suramin derivatives induce aggregation of the prion protein at the cell surface and inhibit PrPSc replication.
Nunziante M; Kehler C; Maas E; Kassack MU; Groschup M; Schätzl HM
J Cell Sci; 2005 Nov; 118(Pt 21):4959-73. PubMed ID: 16219680
[TBL] [Abstract][Full Text] [Related]
22. Evaluation of infective property of recombinant prion protein amyloids in cultured cells overexpressing cellular prion protein.
Kim DH; Lee HM; Ryou C
J Korean Med Sci; 2014 Dec; 29(12):1604-9. PubMed ID: 25469058
[TBL] [Abstract][Full Text] [Related]
23. Prion aggregates transfer through tunneling nanotubes in endocytic vesicles.
Zhu S; Victoria GS; Marzo L; Ghosh R; Zurzolo C
Prion; 2015; 9(2):125-35. PubMed ID: 25996400
[TBL] [Abstract][Full Text] [Related]
24. The prion's elusive reason for being.
Aguzzi A; Baumann F; Bremer J
Annu Rev Neurosci; 2008; 31():439-77. PubMed ID: 18558863
[TBL] [Abstract][Full Text] [Related]
25. Cellular prion protein co-localizes with nAChR beta4 subunit in brain and gastrointestinal tract.
Petrakis S; Irinopoulou T; Panagiotidis CH; Engelstein R; Lindstrom J; Orr-Urtreger A; Gabizon R; Grigoriadis N; Sklaviadis T
Eur J Neurosci; 2008 Feb; 27(3):612-20. PubMed ID: 18279314
[TBL] [Abstract][Full Text] [Related]
26. Binding of disease-associated prion protein to plasminogen.
Fischer MB; Roeckl C; Parizek P; Schwarz HP; Aguzzi A
Nature; 2000 Nov; 408(6811):479-83. PubMed ID: 11100730
[TBL] [Abstract][Full Text] [Related]
27. Polo-like kinase 3 (PLK3) mediates the clearance of the accumulated PrP mutants transiently expressed in cultured cells and pathogenic PrP(Sc) in prion infected cell line via protein interaction.
Wang H; Tian C; Fan XY; Chen LN; Lv Y; Sun J; Zhao YJ; Zhang LB; Wang J; Shi Q; Gao C; Chen C; Shao QX; Dong XP
Int J Biochem Cell Biol; 2015 May; 62():24-35. PubMed ID: 25724737
[TBL] [Abstract][Full Text] [Related]
28. Calpain and other cytosolic proteases can contribute to the degradation of retro-translocated prion protein in the cytosol.
Wang X; Wang F; Sy MS; Ma J
J Biol Chem; 2005 Jan; 280(1):317-25. PubMed ID: 15525638
[TBL] [Abstract][Full Text] [Related]
29. Stressing out the ER: a role of the unfolded protein response in prion-related disorders.
Hetz CA; Soto C
Curr Mol Med; 2006 Feb; 6(1):37-43. PubMed ID: 16472111
[TBL] [Abstract][Full Text] [Related]
30. Could inhibition of the proteasome cause mad cow disease?
Hooper NM
Trends Biotechnol; 2003 Apr; 21(4):144-5. PubMed ID: 12679058
[TBL] [Abstract][Full Text] [Related]
31. Sulfated glycans and elevated temperature stimulate PrP(Sc)-dependent cell-free formation of protease-resistant prion protein.
Wong C; Xiong LW; Horiuchi M; Raymond L; Wehrly K; Chesebro B; Caughey B
EMBO J; 2001 Feb; 20(3):377-86. PubMed ID: 11157745
[TBL] [Abstract][Full Text] [Related]
32. Proteasomal dysfunction and endoplasmic reticulum stress enhance trafficking of prion protein aggregates through the secretory pathway and increase accumulation of pathologic prion protein.
Nunziante M; Ackermann K; Dietrich K; Wolf H; Gädtke L; Gilch S; Vorberg I; Groschup M; Schätzl HM
J Biol Chem; 2011 Sep; 286(39):33942-53. PubMed ID: 21835918
[TBL] [Abstract][Full Text] [Related]
33. Proteasomal degradation and N-terminal protease resistance of the codon 145 mutant prion protein.
Zanusso G; Petersen RB; Jin T; Jing Y; Kanoush R; Ferrari S; Gambetti P; Singh N
J Biol Chem; 1999 Aug; 274(33):23396-404. PubMed ID: 10438517
[TBL] [Abstract][Full Text] [Related]
34. Generation of genuine prion infectivity by serial PMCA.
Weber P; Giese A; Piening N; Mitteregger G; Thomzig A; Beekes M; Kretzschmar HA
Vet Microbiol; 2007 Aug; 123(4):346-57. PubMed ID: 17493773
[TBL] [Abstract][Full Text] [Related]
35. Selective re-routing of prion protein to proteasomes and alteration of its vesicular secretion prevent PrP(Sc) formation.
Filesi I; Cardinale A; Mattei S; Biocca S
J Neurochem; 2007 Jun; 101(6):1516-26. PubMed ID: 17542810
[TBL] [Abstract][Full Text] [Related]
36. Piperazine derivatives inhibit PrP/PrP(res) propagation in vitro and in vivo.
Leidel F; Eiden M; Geissen M; Hirschberger T; Tavan P; Giese A; Kretzschmar HA; Schätzl H; Groschup MH
Biochem Biophys Res Commun; 2014 Feb; 445(1):23-9. PubMed ID: 24502948
[TBL] [Abstract][Full Text] [Related]
37. Molecular Mechanism of the Misfolding and Oligomerization of the Prion Protein: Current Understanding and Its Implications.
Singh J; Udgaonkar JB
Biochemistry; 2015 Jul; 54(29):4431-42. PubMed ID: 26171558
[TBL] [Abstract][Full Text] [Related]
38. Prion protein self-interactions: a gateway to novel therapeutic strategies?
Rigter A; Langeveld JP; van Zijderveld FG; Bossers A
Vaccine; 2010 Nov; 28(49):7810-23. PubMed ID: 20932496
[TBL] [Abstract][Full Text] [Related]
39. Tissue plasminogen activator in brain tissues infected with transmissible spongiform encephalopathies.
Xanthopoulos K; Paspaltsis I; Apostolidou V; Petrakis S; Siao CJ; Kalpatsanidis A; Grigoriadis N; Tsaftaris A; Tsirka SE; Sklaviadis T
Neurobiol Dis; 2005 Nov; 20(2):519-27. PubMed ID: 15922607
[TBL] [Abstract][Full Text] [Related]
40. Development of oligomeric prion-protein aggregates in a mouse model of prion disease.
Sasaki K; Minaki H; Iwaki T
J Pathol; 2009 Sep; 219(1):123-30. PubMed ID: 19479969
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
